Lead Investigator: Stefan Leucht, Klinikum rechts der Isar
Title of Proposal Research: Sex differences in antipsychotic side-effects and efficacy in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
Vivli Data Request: 9736
Funding Source: We are applying for a grant frome the German Ministry of Education and Research. They need an approval from Vivli that we get access to the data.
Potential Conflicts of Interest: In the last 3 years Stefan Leucht has received honoraria as a consultant and/or advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Apsen, Eisai, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Merck Sharpp and Dome, Mitshubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, TEVA. None of these honoraria was directly related to the proposed research project. The project will compare the effects of antipsychotics in men versus women, not differences between antipsychotics. The aim is not to compare the antipsychotics with one another. There is an academic interest to solve this important clinical question but no conflict of interest for the conduct of this project. There is no other financial relationship (grant support, royalties, pending patents) with any of these or other companies. No conflict of interest results in this regard.
Stefan Leucht is the head of a section for evidence based medicine in psychiatry. His work group received research grants from the German Ministry of Education and Research to conduct the proposed project and other systematic reviews and meta-analyses in the field of psychiatry. No conflict of interest arises from this government-funding. The funding agency will not have any role in analysing or interpreting the data and it will not be involved in writing the report.
In any case, potential conflicts of interest will be disclosed when the research is presented and published. Dr. Nomura reports: I have received manuscript fees from Sumitomo Pharma for writing in a clinical bulletin that summarizes research findings from other publications for practicing clinicians. This publication is unrelated to the current study. There is no conflict of interest between this work and the research presented here. All potential conflicts of interest will be fully disclosed during the publication process.
Summary of the Proposed Research:
Schizophrenia is a disabling disorder which affects about 1% of people world-wide. Typical symptoms are hallucinations, people hear voices although nobody is in the room or see things which are not there, and delusions, these are firmly held beliefs that have no basis in facts. For example they believe that someone is following or trying to harm them, also called paranoia. After the acute phase of schizophrenia patients often suffer from reduced motivation and drive, and they withdraw from their friends and families. The main treatment are medicines called antipsychotic drugs which help to reduce these symptoms, but these drugs can have many side effects. Frequent side-effects are movement disorders, for example patients feel stiff or restless, weight gain, sedation or increase in prolactin, a hormone which is important for sexual functions. What is important is that there are differences between men and women when it comes to the effects of these drugs. For example, women are usually smaller and lighter than men. Therefore, they should need lower doses to obtain the same efficacy, and they should be more sensitive for side-effects. Unfortunately, so far studies have rarely analysed the effects of antipsychotics in men and women separately, the results are usually presented in combined form. Therefore, there aren’t clear guidelines on how to use antipsychotic drugs best for each gender. To figure this out, we are planning to look at the information from lots of different studies. We will combine these data in a “network meta-analysis” which is a statistical technique to obtain the average efficacy and side-effects in women and in men. The results could help doctors make better choices for each person, and to create new guidelines for treating people with schizophrenia which take sex difference into account.
Requested Studies:
A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
Data Contributor: AbbVie
Study ID: NCT00073164
Sponsor ID: M02-547
A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia
Data Contributor: GlaxoSmithKline
Study ID: NCT00259870
Sponsor ID: NAA104606
A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia
Data Contributor: GlaxoSmithKline
Study ID: NCT00103727
Sponsor ID: SB-223412/093
The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
Data Contributor: Johnson & Johnson
Study ID: NCT00034749
Sponsor ID: CR003361
Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT00236457
Sponsor ID: CR002026
A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT00297388
Sponsor ID: CR002899
Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Data Contributor: Johnson & Johnson
Study ID: NCT01662310
Sponsor ID: CR100427
A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT00061802
Sponsor ID: CR002890
A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00085748
Sponsor ID: CR004381
A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00299702
Sponsor ID: CR006121
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00077714
Sponsor ID: CR004378
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00074477
Sponsor ID: CR004357
Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00078039
Sponsor ID: CR003379
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00083668
Sponsor ID: CR004375
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00086320
Sponsor ID: CR004384
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents
Data Contributor: Johnson & Johnson
Study ID: NCT00088075
Sponsor ID: CR003370
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00101634
Sponsor ID: CR003562
A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00105326
Sponsor ID: CR002281
A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.
Data Contributor: Johnson & Johnson
Study ID: NCT00111189
Sponsor ID: CR004198
A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00119756
Sponsor ID: CR002350
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00210548
Sponsor ID: CR002353
A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00210717
Sponsor ID: CR004195
CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
Data Contributor: Johnson & Johnson
Study ID: NCT00216476
Sponsor ID: CR002269
Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode
Data Contributor: Johnson & Johnson
Study ID: NCT00216671
Sponsor ID: CR002257
A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT00236379
Sponsor ID: CR002758
Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00249132
Sponsor ID: CR006067
Risperidone Depot (Microspheres) vs. Risperidone Tablets – a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00249223
Sponsor ID: CR006061
Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00253136
Sponsor ID: CR006055
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00334126
Sponsor ID: CR010501
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.
Data Contributor: Johnson & Johnson
Study ID: NCT00397033
Sponsor ID: CR010498
A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.
Data Contributor: Johnson & Johnson
Study ID: NCT00412373
Sponsor ID: CR013099
Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder – an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.
Data Contributor: Johnson & Johnson
Study ID: NCT00495118
Sponsor ID: CR002017
A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Data Contributor: Johnson & Johnson
Study ID: NCT00518323
Sponsor ID: CR002368
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00524043
Sponsor ID: CR013771
Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres
Data Contributor: Johnson & Johnson
Study ID: NCT00526877
Sponsor ID: CR013873
A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00589914
Sponsor ID: CR012289
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00590577
Sponsor ID: CR012550
A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00604279
Sponsor ID: CR013150
A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT00645099
Sponsor ID: CR013189
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia – Open Label Phase
Data Contributor: Johnson & Johnson
Study ID: NCT00645307
Sponsor ID: CR003289
A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS� Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia – Open Label Phase
Data Contributor: Johnson & Johnson
Study ID: NCT00650793
Sponsor ID: CR003376
Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
Data Contributor: Johnson & Johnson
Study ID: NCT00668837
Sponsor ID: CR002944
A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT00992407
Sponsor ID: CR015841
A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Data Contributor: Johnson & Johnson
Study ID: NCT01009047
Sponsor ID: CR016675
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Data Contributor: Johnson & Johnson
Study ID: NCT01193153
Sponsor ID: CR016618
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT01299389
Sponsor ID: CR017026
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT01515423
Sponsor ID: CR100662
A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT01529515
Sponsor ID: CR100717
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
Data Contributor: Johnson & Johnson
Study ID: NCT03345342
Sponsor ID: CR108390
Risperidone versus haloperidol versus placebo in the treatment of schizophrenia
Data Contributor: Johnson & Johnson
Study ID: RIS-USA-1 (RIS-USA-9001)
Sponsor ID: RIS-USA-1 (RIS-USA-9001)
The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia
Data Contributor: Johnson & Johnson
Study ID: RIS-USA-72
Sponsor ID: RIS-USA-72
A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia
Data Contributor: Johnson & Johnson
Study ID: NCT01559272
Sponsor ID: CR012652
A Fixed-Dose Range Safety and Efficacy Study of Olanzapine Versus Haloperidol in the Treatment of Schizophrenia
Data Contributor: Lilly
Study ID: F1D-EW-E003
Sponsor ID: F1D-EW-E003
Olanzapine Versus Clozapine in Refractory Schizophrenic Patients
Data Contributor: Lilly
Study ID: F1D-EW-HGCF
Sponsor ID: F1D-EW-HGCF
A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Data Contributor: Lilly
Study ID: NCT00088478
Sponsor ID: 5984
Olanzapine Versus Placebo and Haloperidol in the Treatment of Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGAD
Sponsor ID: F1D-MC-HGAD
Olanzapine Versus Haloperidol in the Treatment of Schizophrenia and Other Psychotic Disorders
Data Contributor: Lilly
Study ID: F1D-MC-HGAJ
Sponsor ID: F1D-MC-HGAJ
Fixed-Dose Olanzapine Versus Placebo in the Treatment of Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGAP
Sponsor ID: F1D-MC-HGAP
Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders
Data Contributor: Lilly
Study ID: F1D-MC-HGBG
Sponsor ID: F1D-MC-HGBG
A Variable Dose Ranging Safety and Efficacy Study Comparing Olanzapine and Haloperidol in the Treatment of Patients with Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGCJ
Sponsor ID: F1D-MC-HGCJ
A Variable Dose Ranging Safety and Efficacy Study Comparing Olanzapine and Haloperidol in the Treatment of Patients with Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGCU
Sponsor ID: F1D-MC-HGCU
The Acute and Long-Term Efficacy of Olanzapine in First-Episode Psychotic Disorders: A Randomized Double-Blind Comparison with Haloperidol
Data Contributor: Lilly
Study ID: F1D-MC-HGDH
Sponsor ID: F1D-MC-HGDH
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
Data Contributor: Lilly
Study ID: NCT00036088
Sponsor ID: 2347
Study of Olanzapine in Schizophrenic Patients Discontinuing Clozapine Therapy
Data Contributor: Lilly
Study ID: F1D-MC-HGDY
Sponsor ID: F1D-MC-HGDY
Fluoxetine Augmentation in Schizophrenic or Schizoaffective Patients with Depressive or Negative Symptoms Who Are Partial or Nonresponders to Olanzapine
Data Contributor: Lilly
Study ID: F1D-MC-HGFT
Sponsor ID: F1D-MC-HGFT
Olanzapine Relapse Prevention Versus Placebo in the Treatment of Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGGI
Sponsor ID: F1D-MC-HGGI
The Comparative Efficacy of Olanzapine, Risperidone, and Haloperidol for Cognition in Schizophrenia
Data Contributor: Lilly
Study ID: F1D-MC-HGGN
Sponsor ID: F1D-MC-HGGN
Quality of Life in Asian Patients with Schizophrenia: Comparing Olanzapine with Haloperidol
Data Contributor: Lilly
Study ID: F1D-SN-S010
Sponsor ID: F1D-SN-S010
Cost-Effectiveness and Functional Outcomes of Olanzapine in the Treatment of Schizophrenia in Usual Clinical Practice: A Randomized Clinical Study
Data Contributor: Lilly
Study ID: F1D-US-HGGD
Sponsor ID: F1D-US-HGGD
Olanzapine in the Reduction of Hyperprolactinemia and Associated Morbidity in Schizophrenic Patients
Data Contributor: Lilly
Study ID: F1D-US-HGHH
Sponsor ID: F1D-US-HGHH
A Controlled Trial of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenic and Schizoaffective Subjects with Comorbid Depression
Data Contributor: Lilly
Study ID: F1D-US-HGJU
Sponsor ID: F1D-US-HGJU
Efficacy and Safety of Olanzapine Versus Fluphenazine
Data Contributor: Lilly
Study ID: F1D-VI-HGCH
Sponsor ID: F1D-VI-HGCH
A Controlled Trial of Olanzapine Versus Quetiapine in the Treatment of Schizophrenic and Schizoaffective Subjects with Prominent Negative Symptoms
Data Contributor: Lilly
Study ID: FID-US-HGJB
Sponsor ID: FID-US-HGJB
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Data Contributor: Lilly
Study ID: NCT00051298
Sponsor ID: 4066
A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Data Contributor: Lilly
Study ID: NCT00320489
Sponsor ID: 6390
Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study.
Data Contributor: Servier
Study ID: CL2-33138-007
Sponsor ID: CL2-33138-007